Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling.

Yamamizu K, Furuta S, Hamada Y, Yamashita A, Kuzumaki N, Narita M, Doi K, Katayama S, Nagase H, Yamashita JK, Narita M.

Sci Rep. 2013 Nov 14;3:3213. doi: 10.1038/srep03213.

2.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611
3.

Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.

Lai L, Liu J, Zhai D, Lin Q, He L, Dong Y, Zhang J, Lu B, Chen Y, Yi Z, Liu M.

Br J Pharmacol. 2012 Feb;165(4b):1084-96. doi: 10.1111/j.1476-5381.2011.01532.x.

4.

Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.

Han D, Cao C, Su Y, Wang J, Sun J, Chen H, Xu A.

J Ethnopharmacol. 2016 Nov 4;192:406-412. doi: 10.1016/j.jep.2016.09.018. Epub 2016 Sep 17.

PMID:
27649680
5.

SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.

Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N.

Mol Cancer Ther. 2013 Nov;12(11):2378-88. doi: 10.1158/1535-7163.MCT-13-0041. Epub 2013 Aug 29.

6.

CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.

Chung TW, Kim SJ, Choi HJ, Kwak CH, Song KH, Suh SJ, Kim KJ, Ha KT, Park YG, Chang YC, Chang HW, Lee YC, Kim CH.

J Mol Med (Berl). 2013 Feb;91(2):271-82. doi: 10.1007/s00109-012-0952-6. Epub 2012 Aug 31.

PMID:
22935775
7.

Endothelial Cells Require CD98 for Efficient Angiogenesis-Brief Report.

Liao Z, Cantor JM.

Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2163-2166. Epub 2016 Sep 29.

PMID:
27687603
8.
9.

Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.

Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F, Primo L, Hirsch E, Bussolino F, Morello F.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2280-8. doi: 10.1161/ATVBAHA.112.250621. Epub 2012 Jun 21.

10.

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.

Li X, Wang X, Ye H, Peng A, Chen L.

Cancer Chemother Pharmacol. 2012 Sep;70(3):425-37. doi: 10.1007/s00280-012-1923-x. Epub 2012 Jul 20.

PMID:
22814678
11.

Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.

Ma Q, Chen W, Chen W.

Tumour Biol. 2016 May;37(5):6107-16. doi: 10.1007/s13277-015-4473-0. Epub 2015 Nov 26.

PMID:
26611645
12.

Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway.

Cai WB, Zhang Y, Cheng R, Wang Z, Fang SH, Xu ZM, Yang X, Yang ZH, Ma JX, Shao CK, Gao GQ.

PLoS One. 2012;7(12):e53152. doi: 10.1371/journal.pone.0053152. Epub 2012 Dec 31.

13.

Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.

Fan Y, Peng A, He S, Shao X, Nie C, Chen L.

J Chemother. 2013 Oct;25(5):298-308. doi: 10.1179/1973947813Y.0000000079.

PMID:
24070138
14.

Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.

Shinya T, Yokota T, Nakayama S, Oki S, Mutoh J, Takahashi S, Sato K.

J Pharmacol Exp Ther. 2015 Sep;354(3):269-78. doi: 10.1124/jpet.115.224816. Epub 2015 Jun 30.

15.

Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways.

Lee SH, Lee J, Jung MH, Lee YM.

Mol Nutr Food Res. 2013 Feb;57(2):225-34. doi: 10.1002/mnfr.201200489. Epub 2012 Dec 10. Erratum in: Mol Nutr Food Res. 2013 Mar;57(3):556.

PMID:
23229497
16.

Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.

Yang J, Wang Q, Qiao C, Lin Z, Li X, Huang Y, Zhou T, Li Y, Shen B, Lv M, Feng J.

Cell Mol Immunol. 2014 May;11(3):285-93. doi: 10.1038/cmi.2014.6. Epub 2014 Mar 10.

17.

Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation.

Kim KH, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Kim HS, Zhang Y, Ryu SY, Lee MH, Lü J, Kim SH.

Pharm Res. 2011 Mar;28(3):597-609. doi: 10.1007/s11095-010-0311-7. Epub 2010 Nov 10.

PMID:
21063754
18.

VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.

Ueda Y, Yamagishi T, Ikeya H, Hirayama N, Itokawa T, Aozuka Y, Samata K, Nakaike S, Tanaka M, Ono M, Saiki I.

Anticancer Res. 2004 Sep-Oct;24(5A):3009-17.

19.

SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.

Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y.

Clin Cancer Res. 2011 Jul 1;17(13):4439-50. doi: 10.1158/1078-0432.CCR-10-3109. Epub 2011 May 27.

20.

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.

Jung MH, Lee SH, Ahn EM, Lee YM.

Carcinogenesis. 2009 Apr;30(4):655-61. doi: 10.1093/carcin/bgp039. Epub 2009 Feb 18.

PMID:
19228635

Supplemental Content

Support Center